Published in Heart on February 01, 1997
Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med (2010) 3.42
Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest (2003) 2.04
Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy. Heart (1999) 1.45
T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging (2013) 1.35
Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet (2013) 1.27
Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart (2005) 1.24
Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart (2005) 1.24
Familial screening and genetic counselling in hypertrophic cardiomyopathy: the Rotterdam experience. Neth Heart J (2007) 1.23
Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy. Circ Cardiovasc Genet (2009) 1.21
Mutations of the beta myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis. Heart (2003) 1.11
Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol (2016) 1.11
Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy. Am J Cardiol (2011) 0.99
Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart (2014) 0.94
Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy. Circ Cardiovasc Imaging (2014) 0.92
Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands. Neth Heart J (2010) 0.92
Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation. Eur Radiol (2011) 0.91
The role of renin-angiotensin-aldosterone system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic cardiomyopathy. Eur J Hum Genet (2012) 0.87
Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Dutch cardiologists and the care of mutation carriers. Neth Heart J (2009) 0.84
Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart (2005) 0.83
Myocardial structural alteration and systolic dysfunction in preclinical hypertrophic cardiomyopathy mutation carriers. PLoS One (2012) 0.81
Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy. Circ Cardiovasc Genet (2013) 0.81
Counselling issues in familial hypertrophic cardiomyopathy. J Med Genet (1998) 0.81
Structural abnormalities of the left ventricle in hypertrophic cardiomyopathy mutation carriers detectable before the development of hypertrophy. Neth Heart J (2007) 0.81
Abnormal septal convexity into the left ventricle occurs in subclinical hypertrophic cardiomyopathy. J Cardiovasc Magn Reson (2015) 0.79
Phenotype and prognostic correlations of the converter region mutations affecting the β myosin heavy chain. Heart (2015) 0.78
Relationship between Regional Fat Distribution and Hypertrophic Cardiomyopathy Phenotype. PLoS One (2016) 0.77
Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). Eur J Heart Fail (2015) 0.75
Genetic counselling for hypertrophic cardiomyopathy: are we ready for it? Curr Control Trials Cardiovasc Med (2000) 0.75
Echocardiographic characterization of hypertrophic cardiomyopathy in Chinese patients with myosin-binding protein C3 mutations. Exp Ther Med (2017) 0.75
Setting up Multiplex Panels for Genetic Testing of Familial Hypertrophic Cardiomyopathy Based on Linkage Analysis. Iran J Public Health (2016) 0.75
Severe Left Ventricular Hypertrophy, Small Pericardial Effusion, and Diffuse Late Gadolinium Enhancement by Cardiac Magnetic Resonance Suspecting Cardiac Amyloidosis: Endomyocardial Biopsy Reveals an Unexpected Diagnosis. Case Rep Cardiol (2016) 0.75
Insights and challenges in hypertrophic cardiomyopathy, 2012. Herzschrittmacherther Elektrophysiol (2012) 0.75
Radiofrequency catheter ablation is effective for atrial fibrillation patients with hypertrophic cardiomyopathy by decreasing left atrial pressure. J Arrhythm (2017) 0.75
Left atrial wall thickness and outcomes of catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Interv Card Electrophysiol (2014) 0.75
Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation (1996) 9.00
Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation (1995) 6.55
Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med (1995) 4.37
Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu----Val mutation and a 403Arg----Gln mutation. Circulation (1992) 2.67
Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol (1981) 2.37
Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol (1983) 2.34
Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med (1986) 2.00
Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol (1979) 1.55
Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass. Br Heart J (1990) 1.49
A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci U S A (1993) 1.47
Molecular basis of familial cardiomyopathies. Circulation (1995) 1.36
Identification of a mutation in the beta cardiac myosin heavy chain gene in a family with hypertrophic cardiomyopathy. Br Heart J (1993) 1.15
Sudden death in hypertrophic cardiomyopathy with normal left ventricular mass. Br Heart J (1990) 1.06
Relation between extent of left ventricular hypertrophy and age in hypertrophic cardiomyopathy. J Am Coll Cardiol (1989) 1.04
Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. Am J Cardiol (1994) 1.04
The quest for optimal electrocardiography. Tast Force I: standardization of terminology and interpretation. Am J Cardiol (1978) 1.02
Prognostic significance and natural history of left ventricular thrombi in patients with acute anterior myocardial infarction: a two-dimensional echocardiographic study. Circulation (1985) 1.02
Muscular subaortic stenosis. The direct relation between the intraventricular pressure difference and the left ventricular ejection time. Circulation (1967) 1.01
Muscular subaortic stenosis: the temporal relationship between systolic anterior motion of the anterior mitral leaflet and the pressure gradient. Circulation (1982) 0.92
Doppler echocardiography in familial hypertrophic cardiomyopathy: the French Cooperative Study. Echocardiography (1995) 0.84
Echocardiographic assessment of mitral valve size in obstructive hypertrophic cardiomyopathy. Anatomic validation from mitral valve specimen. Circulation (1993) 0.84
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med (1995) 4.37
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med (2000) 4.04
Predicting sudden death in the population: the Paris Prospective Study I. Circulation (1999) 3.80
The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med (1991) 3.17
Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation (2001) 3.12
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J (2003) 2.78
Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J (2004) 2.73
Myoblast transplantation for heart failure. Lancet (2001) 2.71
A second locus for Marfan syndrome maps to chromosome 3p24.2-p25. Nat Genet (1994) 2.71
Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet (1995) 2.52
Long-term outcome in asymptomatic men with exercise-induced premature ventricular depolarizations. N Engl J Med (2000) 2.28
Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J (1999) 2.24
Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in genotyped children. Eur Heart J (1998) 2.20
Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice. Heart (2008) 2.13
Subxiphoid pericardiocentesis guided by contrast two-dimensional echocardiography in cardiac tamponade: experience of 110 consecutive patients. Eur J Echocardiogr (2000) 2.13
Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation (2000) 2.12
Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation (1998) 2.04
Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med (1986) 2.00
Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest (1990) 1.94
Pulmonary embolism detection: prospective evaluation of dual-section helical CT versus selective pulmonary arteriography in 157 patients. Radiology (2000) 1.81
Genotype-phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the beta-myosin heavy chain genes. Eur Heart J (1998) 1.79
Autosomal dominant Marfan-like connective-tissue disorder with aortic dilation and skeletal anomalies not linked to the fibrillin genes. Am J Hum Genet (1993) 1.74
Management of patients with heart failure in clinical practice: differences between men and women. Heart (2007) 1.73
Epidemiology of desmin and cardiac actin gene mutations in a european population of dilated cardiomyopathy. Eur Heart J (2000) 1.68
New CT index to quantify arterial obstruction in pulmonary embolism: comparison with angiographic index and echocardiography. AJR Am J Roentgenol (2001) 1.66
Noninvasive assessment of left ventricular diastolic function: comparative analysis of Doppler echocardiographic and radionuclide angiographic techniques. J Am Coll Cardiol (1986) 1.59
A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res (1998) 1.59
[Adherence to guidelines in CHF therapy in Germany]. Dtsch Med Wochenschr (2005) 1.58
Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol (1987) 1.57
Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol (2013) 1.55
Quantitative assessment of ultrasonic myocardial reflectivity in hypertrophic cardiomyopathy. J Am Coll Cardiol (1991) 1.53
Polyvisceral echinococcosis with cardiac involvement imaged by two-dimensional echocardiography, computed tomography and nuclear magnetic resonance imaging. Am J Cardiol (1987) 1.51
Invasive monitoring combined with two-dimensional echocardiographic study in septic shock. Intensive Care Med (1994) 1.51
Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass. Br Heart J (1990) 1.49
Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (1987) 1.46
Linkage analysis of five fibrillar collagen loci in a large French Marfan syndrome family. J Med Genet (1990) 1.45
[Negative D-dimers and peripheral pulmonary embolism]. Arch Mal Coeur Vaiss (2003) 1.42
Dynamic cardiomyoplasty: effect of discontinuing latissimus dorsi muscle stimulation on left ventricular systolic and diastolic performance and exercise capacity. J Am Coll Cardiol (1995) 1.39
Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation (1995) 1.39
Left ventricular volume analysis for the detection of coronary artery disease during dobutamine stress echocardiography in patients undergoing vascular surgery. Eur J Echocardiogr (2000) 1.38
[Definitions and classification of cardiomyopathies]. Arch Mal Coeur Vaiss (1996) 1.38
[Prognostic factors in dilated cardiomyopathies]. Arch Mal Coeur Vaiss (1988) 1.38
Spectrum of clinical and electrophysiologic features in HNPP patients with the 17p11.2 deletion. Neurology (1999) 1.38
Human Connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor SOX10. Hum Mol Genet (2001) 1.37
Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations. J Med Genet (2003) 1.37
Molecular basis of familial cardiomyopathies. Circulation (1995) 1.36
Risk stratification in chronic heart failure. Eur Heart J (1998) 1.33
Echocardiographic pattern of acute cor pulmonale. Chest (1997) 1.33
Spine deformities in Charcot-Marie-Tooth 4C caused by SH3TC2 gene mutations. Neurology (2006) 1.30
In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion. Circulation (2004) 1.29
Left coronary artery aneurysm and anteroseptal acute myocardial infarction following blunt chest trauma. Eur Heart J (1986) 1.27
Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. J Mol Med (Berl) (1998) 1.27
Central pulse pressure is a major determinant of ascending aorta dilation in Marfan syndrome. Circulation (1999) 1.25
Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy. Am J Cardiol (1983) 1.22
Stem cell transplantation in a patient with late-onset nemaline myopathy and gammopathy. Neurology (2008) 1.20
Coincidence of two genetic forms of Charcot-Marie-Tooth disease in a single family. Neurology (2004) 1.20
Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. Circulation (1996) 1.18
Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. J Am Coll Cardiol (2000) 1.18
Resting heart rate as a predictive risk factor for sudden death in middle-aged men. Cardiovasc Res (2001) 1.15
Acidic fibroblast growth factor in the developing rat embryo. J Cell Biol (1991) 1.15
Usefulness of Doppler echocardiographic assessment of diastolic filling in distinguishing "athlete's heart" from hypertrophic cardiomyopathy. Br Heart J (1992) 1.15
Muscle coenzyme Q10 deficiencies in ataxia with oculomotor apraxia 1. Neurology (2007) 1.13
Acute cor pulmonale in massive pulmonary embolism: incidence, echocardiographic pattern, clinical implications and recovery rate. Intensive Care Med (2001) 1.13
Familial hypertrophic cardiomyopathy. Microsatellite haplotyping and identification of a hot spot for mutations in the beta-myosin heavy chain gene. J Clin Invest (1993) 1.13
Exclusion of HRAS from long QT locus. Nat Genet (1994) 1.11
Peripheral neuropathy and inborn errors of metabolism in adults. J Inherit Metab Dis (2007) 1.11
Skeletal actin mRNA increases in the human heart during ontogenic development and is the major isoform of control and failing adult hearts. J Clin Invest (1991) 1.11
Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. Circulation (1997) 1.10
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia (2005) 1.09
Characterization of a unique genetic variant in the beta1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. J Mol Cell Cardiol (1999) 1.09
Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med (2007) 1.08
Contrast echocardiographic visualization of cough-induced right to left shunt through a patent foramen ovale. J Am Coll Cardiol (1984) 1.08
Cyclic changes in right ventricular output impedance during mechanical ventilation. J Appl Physiol (1985) (1999) 1.08
Aneurysms of sinus of Valsalva: two-dimensional echocardiographic diagnosis and recognition of rupture into the right heart cavities. J Am Coll Cardiol (1984) 1.06
Quantitative two-dimensional echocardiography in massive pulmonary embolism: emphasis on ventricular interdependence and leftward septal displacement. J Am Coll Cardiol (1987) 1.05
The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J Mol Cell Cardiol (1997) 1.05